Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2026)

Ascentage Pharma Group International's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $34.9 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 569.26% year-over-year to $34.9 million; the TTM figure through Dec 2025 stood at $34.9 million (up 569.26% YoY), while the FY2025 annual figure was $35.4 million, up 589.81% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $34.9 million, up from $5.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.2 million in Q4 2023, with the low at $5.2 million in Q4 2024.
• The 3-year median for Current Deferred Revenue is $20.1 million (2025), against an average of $21.4 million.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 87.03% in 2024, then jumped 569.26% in 2025.
• Ascentage Pharma Group International's Current Deferred Revenue stood at $40.2 million in 2023, then plunged by 87.03% to $5.2 million in 2024, then surged by 569.26% to $34.9 million in 2025.
• Business Quant data shows AAPG's Current Deferred Revenue at $34.9 million in Q4 2025, $5.2 million in Q2 2025, and $5.2 million in Q4 2024.